تحميل...
The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials
PURPOSE: PARP inhibition is an exciting new anticancer strategy. As the first PARP inhibitor approved for the treatment of advanced BRCA-mutated ovarian cancer, olaparib has proven to be effective in the treatment of several solid tumors. We performed a meta-analysis of published randomized controll...
محفوظ في:
| الحاوية / القاعدة: | Cancer Manag Res |
|---|---|
| المؤلفون الرئيسيون: | , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Dove Medical Press
2018
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6089112/ https://ncbi.nlm.nih.gov/pubmed/30127642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S169558 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|